Investors

Corporate News & Publications

CLINUVEL's company releases, including archives.

Friday, 09 April 2010 09:00

Lapse of Unlisted Share Options

Lapse of Unlisted Share Options
Wednesday, 07 February 2007 11:00

Appendix 3X Ms Brenda Shanahan

Appendix 3X Ms Brenda Shanahan
Tuesday, 06 February 2007 11:00

New Non-Executive Director

Clinuvel Pharmaceuticals Limited (ASX:CUV) is pleased to announce that Ms Brenda Shanahan has been appointed to the Clinuvel Board of Directors as a non-executive Director. With over 20 years of experience in Australian and overseas economies and share markets, Ms Shanahan brings considerable financial and business expertise to Clinuvel. Ms Shanahan is well known in the business and financial community; her insights willadd significant value to the current Board and the company. Ms Shanahan is currently Chair of both St Vincent’s Health and St Vincent’s Medical Research Institute in Melbourne. She is a nonexecutive Director of JM Financial Group Ltd…
Wednesday, 31 January 2007 11:00

Open Briefing Clinuvel Phase III PLE Trials

Open Briefing Clinuvel Phase III PLE Trials
Clinuvel Pharmaceuticals Limited (ASX:CUV) is pleased to announce that ethics approval has been granted by the United Kingdom’s Central Office for Research Ethics Committees (COREC) to commence a Phase III clinical trial of Clinuvel’s photo-protective drug, CUV1647, in Polymorphous Light Eruption (PLE). This approval follows the company’s recent announcement regarding the approval of the Phase III PLE trial by the Medicines and Healthcare products Regulatory Agency (MHRA). The trial, to be conducted at Hope Hospital in Manchester, UK, is the first site to be granted the necessary regulatory and Medical Ethics Committees (MEC) approval. Patients are currently being recruited. Clinuvel’s…
Tuesday, 30 January 2007 11:00

Appendix 4C December 2006 Quarterly Report

Appendix 4C December 2006 Quarterly Report
Thursday, 25 January 2007 11:00

EGM Results

EGM Results
Clinuvel Pharmaceuticals Limited (ASX:CUV) is pleased to announce that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval, with immediate effect, to commence Phase III clinical trials of Clinuvel’s photo-protective drug, CUV1647, in Polymorphous Light Eruption (PLE). PLE (or PMLE) is a condition also known as moderate to severe sun-poisoning in patients following exposure to UV-radiation. The disease is characterised by a severe skin rash marked by red blisters, vesicles and patches presented on areas of sun exposed skin. The reported incidence of PLE varies between 10-20%. The current therapy available to patients essentially consists of sun…
Monday, 22 January 2007 11:00

Appendix 3B

Appendix 3B
Tuesday, 13 April 2010 06:15

2010 Press Coverage

Written by
{modulepos content2} To receive regular updates, including all of Clinuvel's announcements, you can subscribe to our email database here. DateTitleLink 09/11/2010 Clinuvel taking right approach: FDA Link 31/08/2010 Clinuvel adds to family Link 27/08/2010 Clinuvel seeks thriller repigmentation Link 21/07/2010 Clinuvel - Most interesting logos in Biopharma Link 17/07/2010 SurModics drug delivery tech has day in the sun with Clinuvel Link 16/07/2010 SurModics signs license agreement for UV treatment technology Link 13/07/2010 New drug may bring sufferers light relief Link 13/07/2010 Clinuvel Drug Offers Relief for Rare Light Sensitivity Malady, Study Shows Link 09/07/2010 Clinuvel signs first manufacturing deal for Scenesse…
Page 53 of 53

Quick Links